Gentian Diagnostics ASA (FRA:6FK)

Market Cap	56.30M -24.5%
Revenue (ttm)	16.09M +11.5%
Net Income	-742.85K
EPS	-0.05
Shares Out	n/a
PE Ratio	n/a
Forward PE	26.68
Dividend	0.06 (1.64%)
Ex-Dividend Date	May 6, 2026

Volume	777
Open	3.530
Previous Close	3.490
Day's Range	3.530 - 3.530
52-Week Range	3.080 - 5.200
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 20, 2026

About Gentian Diagnostics ASA

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidne...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2001
• Employees: 64
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6FK

Financial Performance

In 2025, Gentian Diagnostics ASA's revenue was 176.50 million, an increase of 16.07% compared to the previous year's 152.07 million. Earnings were 13.26 million, a decrease of -70.73%.

Financial numbers in NOK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error